Skip to main content

Table 3 Characteristics associated with relative-high quality reporting (items > 9)

From: Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis

 

Reporting items > 9 (N = 7)

Reporting items ≤ 9 (N = 43)

Odds ratio (95% CI)

P value

HM-interventiona

   

P = 0.86

 Single herbal

1 (8.3%)

11 (91.7%)

0.49 (0.052–4.49)

 

 HM-formula

6 (15.8%)

32 (84.2%)

Reference

 

Ethics approvalb

   

P = 0.82

 Yes

4 (17.4%)

19 (82.6%)

1.68 (0.34–8.46)

 

 Not reported

3 (11.1%)

24 (88.9%)

Reference

 

Inform consentc

   

P = 0.97

 Yes

6 (15.4%)

33 (84.6%)

1.82 (0.20–16.9)

 

 Not reported

1 (9.1%)

10 (90.9%)

Reference

 

Sample sized

   

P = 1.00

 1–84

4 (13.8%)

25 (86.2%)

0.96 (0.19–4.83)

 

 84–150

3 (14.3%)

18 (85.7%)

Reference

 

Administration timee

   

P = 0.047

  ≤ 1 month

1 (3.6%)

27 (96.4%)

0.1 (0.01–0.90)

 

  > 1 month

6 (27.3%)

16 (72.7%)

Reference

 

Fundingf

   

P = 0.91

 Non-business

4 (16.7%)

20 (83.3%)

1.53 (0.31–7.69)

 

 Business or not reporting

3 (11.5%)

23 (88.5%)

Reference

 

Therapyg

   

P = 0.72

 Add-on

5 (17.2%)

24 (82.8%)

1.98 (0.53–11.35)

 

 Only placebo

2 (9.5%)

19 (90.5%)

Reference

 
  1. aHM-intervention was dichotomized as singer herbal versus HM formula
  2. bEthics approval was dichotomized as reported versus not reported
  3. cInform consent was dichotomized as reported versus not reported
  4. dThe Sample size was dichotomized as 1–84 versus 84–150 according to the median value
  5. eAdministration time of placebos was dichotomized as ≤ 1 month versus > 1 month according to the median value
  6. fFunding was dichotomized as non-business versus business involvement or not reporting
  7. gThe controlled treatment method was dichotomized as placebo added to other treatments versus only placebo
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172